ATE345788T1 - Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber - Google Patents
Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieberInfo
- Publication number
- ATE345788T1 ATE345788T1 AT02718181T AT02718181T ATE345788T1 AT E345788 T1 ATE345788 T1 AT E345788T1 AT 02718181 T AT02718181 T AT 02718181T AT 02718181 T AT02718181 T AT 02718181T AT E345788 T1 ATE345788 T1 AT E345788T1
- Authority
- AT
- Austria
- Prior art keywords
- virally induced
- treatment
- fever
- inhibitors
- mediated
- Prior art date
Links
- 206010037660 Pyrexia Diseases 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 230000035939 shock Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 2
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 206010061192 Haemorrhagic fever Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105552 | 2001-03-06 | ||
| US27464701P | 2001-03-12 | 2001-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345788T1 true ATE345788T1 (de) | 2006-12-15 |
Family
ID=32523996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02718181T ATE345788T1 (de) | 2001-03-06 | 2002-03-06 | Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040122058A1 (de) |
| EP (1) | EP1420778B1 (de) |
| AT (1) | ATE345788T1 (de) |
| AU (1) | AU2002249261A1 (de) |
| WO (1) | WO2002069960A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US7132398B2 (en) | 2003-05-06 | 2006-11-07 | Dendreon Corporation | Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| PT1691827E (pt) * | 2004-06-25 | 2009-11-23 | Fibrex Medical Res & Dev Gmbh | Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque |
| US8232240B2 (en) * | 2005-02-23 | 2012-07-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
| DE102008010362A1 (de) * | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
| CN104703585A (zh) | 2012-10-09 | 2015-06-10 | 宝洁公司 | 鉴定协同化妆品组合的方法 |
| WO2014059008A1 (en) | 2012-10-09 | 2014-04-17 | The Procter & Gamble Company | Method of identifying or evaluating beneficial actives and compositions containing the same |
| US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
| US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111529532A (zh) * | 2020-05-05 | 2020-08-14 | 华中科技大学同济医学院附属协和医院 | 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用 |
| ES2995196T3 (en) * | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| EP4788839A1 (de) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Verfahren zur prognose und behandlung von patienten mit melanom |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| JP2002534381A (ja) * | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた抗ウィルス法 |
| AU3631500A (en) * | 1999-03-19 | 2000-10-09 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
| CA2362380A1 (en) * | 1999-03-19 | 2000-09-28 | Bristol-Meyers Squibb Pharma Company | Amino-thio-acrylonitriles as mek inhibitors |
-
2002
- 2002-03-06 AU AU2002249261A patent/AU2002249261A1/en not_active Abandoned
- 2002-03-06 WO PCT/EP2002/002467 patent/WO2002069960A2/en not_active Ceased
- 2002-03-06 AT AT02718181T patent/ATE345788T1/de not_active IP Right Cessation
- 2002-03-06 US US10/469,904 patent/US20040122058A1/en not_active Abandoned
- 2002-03-06 EP EP02718181A patent/EP1420778B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1420778B1 (de) | 2006-11-22 |
| WO2002069960A2 (en) | 2002-09-12 |
| WO2002069960A3 (en) | 2003-01-03 |
| US20040122058A1 (en) | 2004-06-24 |
| EP1420778A2 (de) | 2004-05-26 |
| AU2002249261A1 (en) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002249261A1 (en) | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
| NO20045247L (no) | Nukleosidderivater for behandling av hepatitt C-virusinfeksjon | |
| ATE524195T1 (de) | Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen | |
| DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
| BR0209821A (pt) | Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos | |
| ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE602005023587D1 (de) | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen | |
| EP3900717C0 (de) | Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen | |
| SA520420909B1 (ar) | تثبيط بروتين رابط لـ creb (cbp) | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| ATE349448T1 (de) | Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen | |
| EA202192454A1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций | |
| DE602006020775D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE60313803D1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
| DE69730214D1 (de) | Zusammensetzung und verfahren zur behandlung von herpes simplex | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| DE69931784D1 (de) | Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung | |
| EP4247800C0 (de) | N-substituierte 4-(1,3-aryloxazolo-2-yl)phenyl-verbindungen zur behandlung und prophylaxe von hepatitis-b-virusinfektionen | |
| JOP20240149A1 (ar) | مثبطات bcl-2 (الخلية ب لمفومة 2) | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE602006015373D1 (de) | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten | |
| DE50203154D1 (de) | Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |